

# Cornelius J Clancy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7901612/publications.pdf>

Version: 2024-02-01

128  
papers

6,998  
citations

87723

38  
h-index

62479

80  
g-index

132  
all docs

132  
docs citations

132  
times ranked

6811  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Molecular Epidemiology, Natural History, and Long-Term Outcomes of Multidrug-Resistant Enterobacterales Colonization and Infections Among Solid Organ Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2022, 74, 395-406.   | 2.9 | 19        |
| 2  | Remediation of Mucorales-contaminated Healthcare Linens at a Laundry Facility Following an Investigation of a Case Cluster of Hospital-acquired Mucormycosis. <i>Clinical Infectious Diseases</i> , 2022, 74, 1401-1407.  | 2.9 | 4         |
| 3  | Infectious Diseases Society of America Guidance on the Treatment of AmpC $\beta$ -Lactamase-Producing Enterobacterales, Carbapenem-Resistant <i>Acinetobacter baumannii</i> , and <i>Stenotrophomonas maltophilia</i> Infections. <i>Clinical Infectious Diseases</i> , 2022, 74, 2089-2114.  | 2.9 | 262       |
| 4  | Coronavirus Disease 2019-Associated Pulmonary Aspergillosis: Reframing the Debate. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac081.  | 0.4 | 6         |
| 5  | Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases. <i>Open Forum Infectious Diseases</i> , 2022, 9, .   | 0.4 | 25        |
| 6  | Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum $\beta$ -lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR- <i>P. aeruginosa</i> ). <i>Clinical Infectious Diseases</i> , 2022, 75, 187-212. | 2.9 | 182       |
| 7  | Reply to Breazzano et al. <i>Clinical Infectious Diseases</i> , 2022, 75, 1271-1272.  | 2.9 | 1         |
| 8  | A Multicenter Comparison of Carbapenem-Nonsusceptible Enterobacterales and <i>Pseudomonas aeruginosa</i> Rates in the US (2016 to 2020): Facility-Reported Rates versus Rates Based on Updated Clinical Laboratory and Standards Institute Breakpoints. <i>Microbiology Spectrum</i> , 2022, 10, .  | 1.2 | 4         |
| 9  | Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000–2017. <i>Clinical Infectious Diseases</i> , 2021, 73, e4521-e4530.  | 2.9 | 39        |
| 10 | Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2021, 73, 416-426.  | 2.9 | 37        |
| 11 | Impact of Revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America Clinical Practice Guidelines on the Treatment of <i>Clostridium difficile</i> Infections in the United States. <i>Clinical Infectious Diseases</i> , 2021, 72, 1944-1949.   | 2.9 | 31        |
| 12 | Antibacterial Drug Development Trends in the United States from 1980–2019: Agents Active Against Carbapenem-resistant Gram-negative Bacteria as Case Study. <i>Clinical Infectious Diseases</i> , 2021, 72, e437-e438.  | 2.9 | 0         |
| 13 | A First Draft of the History of Treating Coronavirus Disease 2019: Use of Repurposed Medications in United States Hospitals. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa617.  | 0.4 | 2         |
| 14 | Reply to Turner. <i>Clinical Infectious Diseases</i> , 2021, 72, 2065-2066.   | 2.9 | 0         |
| 15 | Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum $\beta$ -lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR- <i>P. aeruginosa</i> ). <i>Clinical Infectious Diseases</i> , 2021, 72, e169-e183.    | 2.9 | 292       |
| 16 | Fungal infections in lung transplantation. <i>Journal of Thoracic Disease</i> , 2021, 13, 6695-6707.  | 0.6 | 13        |
| 17 | Bacterial Superinfections Among Persons With Coronavirus Disease 2019: A Comprehensive Review of Data From Postmortem Studies. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab065.  | 0.4 | 54        |
| 18 | <i>Candida</i> Empyema Thoracis at Two Academic Medical Centers: New Insights Into Treatment and Outcomes. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa656.  | 0.4 | 16        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum $\beta$ -lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR- <i>P. aeruginosa</i> ). <i>Clinical Infectious Diseases</i> , 2021, 72, 1109-1116. | 2.9 | 251       |
| 20 | <i>In Vitro</i> Susceptibility of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> following Treatment-Emergent Resistance to Ceftolozane-Tazobactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .  | 1.4 | 31        |
| 21 | Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021, 47, 819-834.  | 3.9 | 106       |
| 22 | Invasive mould disease in fatal COVID-19: a systematic review of autopsies. <i>Lancet Microbe</i> , The, 2021, 2, e405-e414.   | 3.4 | 62        |
| 23 | Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials?. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab441.  | 0.4 | 3         |
| 24 | Exploratory Cost-Effectiveness Analysis for Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections: Is Linezolid or Daptomycin Favored Over Vancomycin?. <i>Clinical Drug Investigation</i> , 2021, 41, 885-894.   | 1.1 | 3         |
| 25 | Introduction of the BNT162b2 vaccine during a COVID-19 nursing home outbreak. <i>American Journal of Infection Control</i> , 2021, 49, 1237-1241.  | 1.1 | 4         |
| 26 | Invasive Pulmonary Aspergillosis Complicating Noninfluenza Respiratory Viral Infections in Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab478.  | 0.4 | 9         |
| 27 | Discordance Among Antibiotic Prescription Guidelines Reflects a Lack of Clear Best Practices. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa571.  | 0.4 | 1         |
| 28 | Sequence type-258 carbapenem-resistant <i>Klebsiella pneumoniae</i> isolates in which ceftazidime-avibactam resistance emerged are not hypermutators. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114954.  | 0.8 | 1         |
| 29 | Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. <i>Clinical Infectious Diseases</i> , 2020, 71, 667-671.  | 2.9 | 71        |
| 30 | Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.  | 2.9 | 1,429     |
| 31 | PRO: The COVID-19 pandemic will result in increased antimicrobial resistance rates. <i>JAC-Antimicrobial Resistance</i> , 2020, 2, dlaa049.  | 0.9 | 67        |
| 32 | It's worse than we thought: the US market for novel Gram-negative antibiotics. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1009-1010.   | 4.6 | 4         |
| 33 | Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect?. <i>Clinical Infectious Diseases</i> , 2020, 71, 2736-2743.  | 2.9 | 203       |
| 34 | Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .  | 1.4 | 18        |
| 35 | Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020, 46, 1524-1535.  | 3.9 | 278       |
| 36 | What Is New in Candida Infections? T2Candida, Antifungal Stewardship, and Candida auris. <i>Current Treatment Options in Infectious Diseases</i> , 2020, 12, 1-12.   | 0.8 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Suprapubic catheter placement improves antimicrobial stewardship among Veterans Affairs nursing care facility residents. <i>American Journal of Infection Control</i> , 2020, 48, 1264-1266.   | 1.1 | 2         |
| 38 | Impact of the Coronavirus Disease 2019 Pandemic on Outpatient Antibiotic Prescriptions in the United States. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa575.   | 0.4 | 38        |
| 39 | Genetic diversity of clinical and environmental Mucorales isolates obtained from an investigation of mucormycosis cases among solid organ transplant recipients. <i>Microbial Genomics</i> , 2020, 6, .  | 1.0 | 10        |
| 40 | Estimating the Size of the U.S. Market for New Antibiotics with Activity against Carbapenem-Resistant <i>Enterobacteriaceae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .   | 1.4 | 22        |
| 41 | Estimating the Treatment of Carbapenem-Resistant <i>Enterobacteriaceae</i> Infections in the United States Using Antibiotic Prescription Data. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz344.  | 0.4 | 51        |
| 42 | Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of <i>Klebsiella pneumoniae</i> in a Hollow Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .  | 1.4 | 13        |
| 43 | Rapid diagnosis of invasive candidiasis: ready for prime-time?. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 546-552.   | 1.3 | 10        |
| 44 | Effects of KPC Variant and Porin Genotype on the <i>In Vitro</i> Activity of Meropenem-Vaborbactam against Carbapenem-Resistant <i>Enterobacteriaceae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .   | 1.4 | 61        |
| 45 | Spontaneous Mutational Frequency and <i>FKS</i> Mutation Rates Vary by Echinocandin Agent against <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .   | 1.4 | 30        |
| 46 | How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. <i>Clinical Infectious Diseases</i> , 2019, 68, 850-853.   | 2.9 | 31        |
| 47 | Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant <i>Enterobacteriaceae</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, . | 1.4 | 203       |
| 48 | T2 magnetic resonance for the diagnosis of bloodstream infections: charting a path forward. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, iv2-iv5.  | 1.3 | 65        |
| 49 | PCR-Based Methods for the Diagnosis of Invasive Candidiasis: Are They Ready for Use in the Clinic?. <i>Current Fungal Infection Reports</i> , 2018, 12, 71-77.   | 0.9 | 1         |
| 50 | Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant <i>Enterobacteriaceae</i> and <i>Pseudomonas aeruginosa</i> . <i>Journal of Clinical Microbiology</i> , 2018, 56, .               | 1.8 | 55        |
| 51 | 247. Sustaining Excellence of Care During a Fluid Shortage: Snapshot of Antibiotic Mitigation Strategies Following Hurricane Maria. <i>Open Forum Infectious Diseases</i> , 2018, 5, S105-S105.  | 0.4 | 0         |
| 52 | Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .   | 1.4 | 29        |
| 53 | Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant <i>Enterobacteriaceae</i> <i>In Vitro</i> or Suppress Emergence of Ceftazidime-Avibactam Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .             | 1.4 | 22        |
| 54 | <i>In Vitro</i> Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible <i>Klebsiella pneumoniae</i> Isolates with Variant KPC-3 Carbapenemases. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .             | 1.4 | 84        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. <i>Clinical Infectious Diseases</i> , 2017, 64, S30-S35.   | 2.9 | 114       |
| 56 | Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .   | 1.4 | 122       |
| 57 | Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .   | 1.4 | 347       |
| 58 | Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: Clinical Effectiveness and Evolution of Resistance. <i>Clinical Infectious Diseases</i> , 2017, 65, 110-120.   | 2.9 | 224       |
| 59 | Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne <i>bla</i> <sub>KPC-3</sub> Mutations during Treatment of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .                      | 1.4 | 334       |
| 60 | <i>Klebsiella pneumoniae</i> Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from $\beta$ -Lactamase Protein Engineering. <i>MBio</i> , 2017, 8, .                | 1.8 | 93        |
| 61 | Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .   | 1.4 | 73        |
| 62 | Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .  | 1.4 | 36        |
| 63 | Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .  | 1.4 | 72        |
| 64 | Emergence of <i>Candida auris</i> : An International Call to Arms. <i>Clinical Infectious Diseases</i> , 2017, 64, 141-143.  | 2.9 | 106       |
| 65 | Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> : A Case Report and Review of Literature. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx101. | 0.4 | 103       |
| 66 | Therapeutic Drug Monitoring (TDM) of Suspension (SUS), Extended-Release (ER), and Intravenous (IV) Posaconazole (POS) at a Large Transplant Center. <i>Open Forum Infectious Diseases</i> , 2017, 4, S297-S297.  | 0.4 | 0         |
| 67 | Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT1): A Prospective, Multicenter Study of the T2Candida Panel. <i>Open Forum Infectious Diseases</i> , 2017, 4, S52-S52.   | 0.4 | 0         |
| 68 | <i>Candida albicans</i> Transcriptional Profiling Within Biliary Fluid From a Patient With Cholangitis, Before and After Antifungal Treatment and Surgical Drainage. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw120.  | 0.4 | 0         |
| 69 | Outcomes of <i>Candida</i> Empyema Correlate with Source of Infection. <i>Open Forum Infectious Diseases</i> , 2016, 3, .  | 0.4 | 0         |
| 70 | Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment. <i>PLoS ONE</i> , 2016, 11, e0153247.  | 1.1 | 107       |
| 71 | Daptomycin Non-susceptible VRE: Problematic Pathogen or Misclassified Microbe?. <i>Open Forum Infectious Diseases</i> , 2016, 3, .   | 0.4 | 0         |
| 72 | Epidemiology of Azole-Resistance and CYP51A Mutations in <i>Aspergillus</i> Isolates Recovered from Lung Transplant Recipients Who Received Voriconazole Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2016, 3, .   | 0.4 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Impact of Rectal Colonization With Highly Drug-Resistant Enterobacteriaceae on Post-Transplant Infections: The Carbapenem-Resistant Enterobacteriaceae Carriage in Solid Organ Transplant (CREST) Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, .  | 0.4 | 0         |
| 74 | Rapid Emergence of Ceftazidime-Avibactam Resistance Due to blaKPC-3 Mutations During Treatment (tx) of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> (CRKp) Infections. <i>Open Forum Infectious Diseases</i> , 2016, 3, .   | 0.4 | 1         |
| 75 | Emerging Waves of Carbapenem Resistance Among Gram-Negative Pathogens at a Tertiary Center. <i>Open Forum Infectious Diseases</i> , 2016, 3, .   | 0.4 | 0         |
| 76 | Pharmacokinetics of Posaconazole Suspension in Lung Transplant Patients with and without Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3558-3562.  | 1.4 | 14        |
| 77 | More Than Just Candidemia: The Spectrum of Invasive Candidiasis t 2 University Medical Centers in the United States. <i>Open Forum Infectious Diseases</i> , 2016, 3, .  | 0.4 | 0         |
| 78 | Highly Dynamic and Specific Phosphatidylinositol 4,5-Bisphosphate, Septin, and Cell Wall Integrity Pathway Responses Correlate with Caspofungin Activity against <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3591-3600.   | 1.4 | 18        |
| 79 | Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3187-3192.   | 1.4 | 41        |
| 80 | Rapid Detection of <i>FKS</i> -Associated Echinocandin Resistance in <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6573-6577.   | 1.4 | 53        |
| 81 | <i>Candida albicans</i> Pathogenesis: Fitting within the Host-Microbe Damage Response Framework. <i>Infection and Immunity</i> , 2016, 84, 2724-2739.  | 1.0 | 144       |
| 82 | Clinical Outcomes of Bloodstream Infections Due to Vancomycin-Resistant <i>Enterococcus faecium</i> . <i>Open Forum Infectious Diseases</i> , 2016, 3, .   | 0.4 | 0         |
| 83 | Association between the Presence of Aminoglycoside-Modifying Enzymes and <i>In Vitro</i> Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against <i>Klebsiella pneumoniae</i> Carbapenemase- and Extended-Spectrum- $\beta$ -Lactamase-Producing <i>Enterobacter</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5208-5214. | 1.4 | 38        |
| 84 | Evaluation of the <i>In Vitro</i> Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant <i>Pseudomonas aeruginosa</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3227-3231.   | 1.4 | 85        |
| 85 | Coordination of <i>Candida albicans</i> Invasion and Infection Functions by Phosphoglycerol Phosphatase Rhr2. <i>Pathogens</i> , 2015, 4, 573-589.   | 1.2 | 21        |
| 86 | Doripenem MICs and ompK36 Porin Genotypes of Sequence Type 258, KPC-Producing <i>Klebsiella pneumoniae</i> May Predict Responses to Carbapenem-Colistin Combination Therapy among Patients with Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1797-1801.  | 1.4 | 25        |
| 87 | Effects of <i>Klebsiella pneumoniae</i> Carbapenemase Subtypes, Extended-Spectrum $\beta$ -Lactamases, and Porin Mutations on the <i>In Vitro</i> Activity of Ceftazidime-Avibactam against Carbapenem-Resistant <i>K. pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5793-5797.  | 1.4 | 104       |
| 88 | Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia. <i>Annals of Pharmacotherapy</i> , 2015, 49, 1068-1074.  | 0.9 | 25        |
| 89 | Rate of <i>FKS</i> Mutations among Consecutive <i>Candida</i> Isolates Causing Bloodstream Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7465-7470.  | 1.4 | 48        |
| 90 | Delinking CARD9 and IL-17: CARD9 Protects against <i>Candida tropicalis</i> Infection through a TNF- $\alpha$ -Dependent, IL-17-Independent Mechanism. <i>Journal of Immunology</i> , 2015, 195, 3781-3792.  | 0.4 | 38        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Abdominal Candidiasis Is a Hidden Reservoir of Echinocandin Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7601-7605.  | 1.4 | 89        |
| 92  | KPC-Producing <i>Klebsiella pneumoniae</i> Strains That Harbor AAC(6)-Ib Exhibit Intermediate Resistance to Amikacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7597-7600.  | 1.4 | 17        |
| 93  | Doripenem, Gentamicin, and Colistin, Alone and in Combinations, against Gentamicin-Susceptible, KPC-Producing <i>Klebsiella pneumoniae</i> Strains with Various <i>ompK36</i> Genotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3521-3525. | 1.4 | 34        |
| 94  | <i>Candida glabrata</i> Intra-Abdominal Candidiasis Is Characterized by Persistence within the Peritoneal Cavity and Abscesses. <i>Infection and Immunity</i> , 2014, 82, 3015-3022.   | 1.0 | 36        |
| 95  | Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Strains Exhibit Diversity in Aminoglycoside-Modifying Enzymes, Which Exert Differing Effects on Plazomicin and Other Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4443-4451.           | 1.4 | 99        |
| 96  | Mucosal Immunity to <i>Candida albicans</i> . , 0, , 137-154.  |     | 4         |
| 97  | Salivary Histatins: Structure, Function, and Mechanisms of Antifungal Activity. , 0, , 185-194.  |     | 4         |
| 98  | The Cell Wall: Glycoproteins, Remodeling, and Regulation. , 0, , 195-223.  |     | 5         |
| 99  | Stress Responses in <i>Candida</i> . , 0, , 225-242.   |     | 3         |
| 100 | Adhesins in Opportunistic Fungal Pathogens. , 0, , 243-P2.   |     | 9         |
| 101 | Gene Expression during the Distinct Stages of Candidiasis. , 0, , 283-298.   |     | 1         |
| 102 | An Introduction to the Medically Important <i>Candida</i> Species. , 0, , 9-25.  |     | 16        |
| 103 | Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use. , 0, , 343-371.  |     | 3         |
| 104 | The Impact of Antifungal Drug Resistance in the Clinic. , 0, , 373-385.  |     | 1         |
| 105 | Insights in Antifungal Drug Discovery. , 0, , 387-401.   |     | 2         |
| 106 | Mucosal Candidiasis. , 0, , 417-427.   |     | 4         |
| 107 | Systemic Candidiasis: Candidemia and Deep-Organ Infections. , 0, , 429-441.  |     | 3         |
| 108 | The Epidemiology of Invasive Candidiasis. , 0, , 449-480.  |     | 6         |

| #   | ARTICLE   | IF | CITATIONS |
|-----|---|----|-----------|
| 109 | Cell Cycle and Growth Control in <i>Candida</i> Species. , 0, , 101-124.  |    | 1         |
| 110 | Cool Tools 3: Large-Scale Genetic Interaction Screening in <i>Candida albicans</i> . , 0, , 497-500.                            |    | 0         |
| 111 | Cool Tools 4: Imaging <i>Candida</i> Infections in the Live Host. , 0, , 501-P1.  |    | 0         |
| 112 | Encounters with Mammalian Cells: Survival Strategies of <i>Candida</i> Species. , 0, , 261-P1.                                  |    | 1         |
| 113 | <i>Candida</i> spp. in Microbial Populations and Communities: Molecular Interactions and Biological Importance. , 0, , 317-330. |    | 0         |
| 114 | New Developments in Diagnostics and Management of Invasive Candidiasis. , 0, , 443-448.   |    | 0         |
| 115 | Biofilm Formation in <i>Candida albicans</i> . , 0, , 299-315.  |    | 0         |
| 116 | Genome Instability and DNA Repair. , 0, , 57-P2.  |    | 0         |
| 117 | Cool Tools 2: Development of a <i>Candida albicans</i> Cell Surface Protein Microarray. , 0, , 489-496.                         |    | 0         |
| 118 | Immunology of Invasive Candidiasis. , 0, , 125-136.   |    | 2         |
| 119 | Multidrug Resistance Transcriptional Regulatory Networks in <i>Candida</i> . , 0, , 403-416.                                    |    | 0         |
| 120 | Switching and Mating. , 0, , 75-90.   |    | 0         |
| 121 | Vaccines and Passive Immunity against Candidiasis. , 0, , 171-184.  |    | 0         |
| 122 | <i>Candida</i> : What Should Clinicians and Scientists Be Talking About?. , 0, , 1-8.   |    | 6         |
| 123 | The Genetic Code of the <i>Candida</i> CTG Clade. , 0, , 45-55.   |    | 0         |
| 124 | Innate Immunity to <i>Candida</i> Infections. , 0, , 155-170.   |    | 0         |
| 125 | Cool Tools 5: The <i>Candida albicans</i> ORFeome Project. , 0, , 505-510.  |    | 1         |
| 126 | Comparative Genomics of <i>Candida</i> Species. , 0, , 27-43.   |    | 0         |



| #   | ARTICLE  | IF | CITATIONS |
|-----|--|----|-----------|
| 127 | Detection and Clinical Significance of Variability among Candida Isolates. , 0, , 91-99. |    | 0         |
| 128 | Back to the Future: Candida Mitochondria and Energetics. , 0, , 331-341.                 |    | 1         |